triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-06. Anything still debated is marked as such rather than presented as settled.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
SRM has been used to identify the proteins encoded by wild-type and mutant genes (mutant proteins) and quantify their absolute copy numbers in tumors and biological fluids, thus answering the basic questions about the absolute copy number of proteins in a single cell, which will be essential in digital modelling of mammalian cells and human body, and the relative levels of genetically abnormal proteins in tumors, and proving useful for diagnostic applications. SRM has also been used as a method of triggering full product ion scans of peptides to either a) confirm the specificity of the SRM transition, or b) detect specific post-translational modifications which are below the limit of detection of standard MS analyses. In 2017, SRM has been developed to be a highly sensitive and reproducible mass spectrometry-based protein targeted detection platform (entitled "SAFE-SRM"), and it has been demonstrated that the SRM-based new pipeline has major advantages in clinical proteomics applications over traditional SRM pipelines, and it has demonstrated a dramatically improved diagnostic performance over that from antibody-based protein biomarker diagnostic methods, such as ELISA.
Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder, as well as aggressive and self-injurious behaviors associated with autism spectrum disorder. It is taken either by mouth or by injection (i.e., subcutaneous or intramuscular). The injectable versions are long-acting and last for 2–4 weeks. Common side effects include weight gain, drowsiness, fatigue, insomnia, dry mouth, constipation, elevated prolactin levels, and restlessness. Serious side effects may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, and high blood sugar levels. In older people with psychosis as a result of dementia, it may increase the risk of death. It is unknown if it is safe for use in pregnancy. Its mechanism of action is not entirely clear, but is believed to be related to its action as a dopamine and serotonin antagonist. Study of risperidone began in the late 1980s and it was approved for sale in the United States in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 176th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
1 November – A pooled analysis indicates that globally over half of all preschool-aged children and over two-thirds of all nonpregnant women of reproductive age are deficient in at least one of three micronutrients each. The study notes required data is scarce and such deficiencies can constrain physical and (neurocognitive) development and compromise health. 2 November – Scientists show that cells move faster in thicker (higher viscosity) fluids. Cancer cells can form memory of extracellular fluid, helping them to form distant cancerous colonies more efficiently when exposed to fluids of higher viscosities. 3 November – Astronomers using the IXPE space observatory report that 4U 0142+61, a magnetar found 13,000 light-years from Earth, likely has a solid surface with no atmosphere. 4 November – The discovery of Gaia BH1, a binary system containing what is likely the closest known black hole to Earth, is reported by astronomers in the U.S. 6–18 November – The 2022 United Nations Climate Change Conference (COP27) on climate change mitigation takes place in Sharm el-Sheikh, Egypt. 7 November The first clinical trial of laboratory-grown red blood cells transfused into people begins. Scientists warn about summarized effects of climate change on insects, among other novel stressors, which may "drastically reduce our ability to build a sustainable future based on healthy, functional ecosystems", providing several recommended mitigation options. The development of organic artificial neurons that function in and with biological systems, partly (see e.g.
New methods for tracking biomolecules have been developed including the use of colorimetric biosensors, photochromic compounds, biomaterials, and electrochemical sensors. Fluorescent labeling is also a common method in which applications have expanded to enzymatic labeling, chemical labeling, protein labeling, and genetic labeling.
==== Stunted growth ==== Untreated OSA in children can also lead to stunted growth. When sleep is disrupted in children who are still growing, there can be significant consequences. Human growth hormone (HGH) is secreted during the night, especially during deep, non-REM sleep. If this is disrupted, growth hormone secretion may be compromised; thus, growth may not occur normally, and children may become shorter than their peers.
Sources: en.wikipedia.org
In the study of anatomy, viscera (sing.: viscus) refers to the internal organs of the abdominal, thoracic, and pelvic cavities. The abdominal organs may be classified as solid organs or hollow organs. The solid organs are the liver, pancreas, spleen, kidneys, and adrenal glands. The hollow organs of the abdomen are the stomach, intestines, gallbladder, bladder, and rectum. In the thoracic cavity, the heart is a hollow, muscular organ. Splanchnology is the study of the viscera. The term "visceral" is contrasted with the term "parietal", meaning "of or relating to the wall of a body part, organ or cavity". The two terms are often used in describing a membrane or piece of connective tissue, referring to the opposing sides.
Alternatives to the above closed-channel continuous-flow systems include novel open structures, where discrete, independently controllable droplets are manipulated on a substrate using electrowetting. Following the analogy of digital microelectronics, this approach is referred to as digital microfluidics. Le Pesant et al. pioneered the use of electrocapillary forces to move droplets on a digital track. The "fluid transistor" pioneered by Cytonix also played a role. The technology was subsequently commercialised by Duke University. By using discrete unit-volume droplets, a microfluidic function can be reduced to a set of repeated basic operations, i.e., moving one unit of fluid over one unit of distance. This "digitisation" method facilitates the use of a hierarchical and cell-based approach for microfluidic biochip design. Therefore, digital microfluidics offers a flexible and scalable system architecture as well as high fault-tolerance capability. Moreover, because each droplet can be controlled independently, these systems also have dynamic reconfigurability, whereby groups of unit cells in a microfluidic array can be reconfigured to change their functionality during the concurrent execution of a set of bioassays. Although droplets are manipulated in confined microfluidic channels, since the control on droplets is not independent, it should not be confused as "digital microfluidics". One common actuation method for digital microfluidics is electrowetting-on-dielectric (EWOD).
=== GGQ catalytic site === The catalytic site that is responsible for the hydrolysis of the peptidyl tRNA is the GGQ site on eRF1. Current understanding of the GGQ site states that it enters the P-site of the ribosome, which is where the peptidyl tRNA is located, after a conformational change caused by the hydrolysis of GTP by eRF3. Furthermore, any mutation to the GGQ site renders eRF1 nonfunctional, thus the cells ability to successfully terminate Translation. This is due to the two glycine residues in GGQ to adopt a torsional angle that is only possible with two glycines. Without the proper angle, the active site for the reaction won't be able to function properly. In order nascent protein to be released the GGQ site needs to recruit a water molecule into the active site of the reaction. The method of recruitment for a single water molecule is still not understood completely. Once in position, the water molecule acts as a nucleophile, and attacks the carbonyl group of the ester bond between the nascent protein and the tRNA. The hydrolysis of the ester bond causes the release of the nascent protein and the disassembly of the ribosome and termination complex.
It is a hard technique, which tends to break down large molecule ions during flight, since large molecules are particularly easy to fragment. Furthermore, large molecules are hard to volatilize without being degraded by heat.
The Kisrawan campaigns were a series of Mamluk military expeditions against the mountaineers of the Kisrawan, as well as the neighboring areas of Byblos and the Jurd, in Mount Lebanon. The offensives were launched in 1292, 1300 and 1305. The mountaineers were Shia Muslim, Alawite, Maronite and Druze tribesmen who historically acted autonomously of any central authority. The Maronites in particular had maintained close cooperation with the last Crusader state, the County of Tripoli. After the fall of Tripoli to the Mamluks in 1289, the mountaineers would often block the coastal road between Tripoli and Beirut, prompting the first Mamluk expedition in 1292 under the viceroy of Egypt, Baydara. During that campaign, the Mamluks, spread along the coastal road and cut off from each other at various points, were constantly harried by the mountaineers, who confiscated their weapons, horses and money. Baydara withdrew his men only after paying off the mountain chiefs. In modern Lebanese historical narratives, the Kisrawan campaigns have been a source of controversy by historians from different religious groups. Maronite, Shia and Druze historians have each sought to emphasize the roles of their respective confessional group, over each other, in defending the autonomy of the Kisrawan from Mamluk outsiders. In writings by Sunni Muslim authors, the Mamluks are portrayed as the legitimate Muslim state working to incorporate Mount Lebanon into the rest of the Islamic realm.
Sources: en.wikipedia.org
The Center for Biologics Evaluation and Research is the branch of the FDA responsible for ensuring the safety and efficacy of biological therapeutic agents. These include blood and blood products, vaccines, allergenics, cell and tissue-based products, and gene therapy products. New biologics are required to go through a premarket approval process called a Biologics License Application (BLA), similar to that for drugs. The original authority for government regulation of biological products was established by the 1902 Biologics Control Act, with additional authority established by the 1944 Public Health Service Act. Along with these Acts, the Federal Food, Drug, and Cosmetic Act applies to all biologic products, as well. Originally, the entity responsible for regulation of biological products resided under the National Institutes of Health; this authority was transferred to the FDA in 1972.
== Neutron crystallography == Hydrogen–deuterium exchange of fast-exchanging species (e.g. hydroxyl groups) can be measured at atomic resolution quantitatively by neutron crystallography, and in real time if exchange is conducted during the diffraction experiment. High intensity neutron beams are generally generated by spallation at linac particle accelerators such as the Spallation Neutron Source. Neutrons diffract crystals similarly to X-rays and can be used for structural determination. Hydrogen atoms, with between one and zero electrons in a biological setting, diffract X-rays poorly and are effectively invisible under normal experimental conditions. Neutrons scatter from atomic nuclei, and are therefore capable of detecting hydrogen and deuterium atoms. Hydrogen atoms are routinely replaced with deuterium, which introduce a strong and positive scattering factor. It is often sufficient to replace only the solvent and labile hydrogen atoms in a protein crystal by vapor diffusion. In such a structure the occupancy of an exchangeable deuterium atom in a crystal will refine from 0-100%, directly quantifying the amount of exchange.
Nuclear magnetic resonance (NMR) is one of the most common methods to determine the physical and chemical properties of atoms by detecting the radio frequency absorbed and subsequent relaxation of nuclei in a magnetic field. This is one of the most commonly used characterization techniques and has applications in numerous fields. Primarily, the strong magnetic fields are generated by supercooling electromagnets, although there are spectrometers that do not require cryogens. In traditional superconducting solenoids, liquid helium is used to cool the inner coils because it has a boiling point of around 4 K at ambient pressure. Inexpensive metallic superconductors can be used for the coil wiring. So-called high-temperature superconducting compounds can be made to super conduct with the use of liquid nitrogen, which boils at around 77 K. Magnetic resonance imaging (MRI) is a complex application of NMR where the geometry of the resonances is deconvoluted and used to image objects by detecting the relaxation of protons that have been perturbed by a radio-frequency pulse in the strong magnetic field. This is most commonly used in health applications. Cryogenic electron microscopy (cryoEM) is a popular method in structural biology for elucidating the structures of proteins, cells, and other biological systems. Samples are plunge-frozen into a cryogen such as liquid ethane cooled by liquid nitrogen, and are then kept at liquid nitrogen temperature as they are inserted into an electron microscope for imaging. Electron microscopes are also themselves cooled by liquid nitrogen.
Mold is a dangerous library pest because of the damage it causes to the collections. Mold thrives off of paper and books; these objects provide the fungi a source of nutrition, namely the sugar and starches present in the cellulose materials. Mold feeds on cloth, leather, glues, adhesives, cellulose starch and starches in the sizing. Frequently, mold is noticed on the bindings long before it begins on the text blocks. By feeding on books, mold can cause the paper to become thin, soft, or spongy. Images and decorative elements can be completely destroyed or, at the very least, become stained.
All these reports were written in context of Jesuit missions in South America, specially the Mainas missions, in Latin and sent only to Rome, so their audience was not very large and they were promptly lost in the archives. For this reason, ayahuasca did not receive attention for the entire subsequent century.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.